China's Harbour BioMed rakes in $102.7m to speed up COVID-19 pipeline

People walk on the street in Macau wearing face masks to protect them to be infected with coronavirus. Source: Macau Photo Agency/Unsplash

Shanghai-based biopharmaceutical firm Harbour BioMed (HBM) on Thursday announced the completion of a Series C round of financing at $102.7 million led by Hudson Bay Capital, an asset management firm in New York and London.

The Series C round comes less than four months after HBM completed a Series B+ round at $75 million in mid-March, underlining the company’s ambition in speeding up the development of its portfolio for the treatment of next-generation biologics targeting cancer, immunologic diseases, and the COVID-19.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter